Abstract
Leukemia stem cells (LSCs) are likely to be the source for both therapeutic resistance and relapse in myeloid malignancies. As reported in this issue of Cell Stem Cell, Lagadinou et al. (2013) and Goff et al. (2013) support selective targeting of LSCs by small molecule antagonists of anti-apoptotic BCL-2 family proteins.
Copyright © 2013 Elsevier Inc. All rights reserved.
MeSH terms
-
Humans
-
Leukemia / pathology*
-
Leukemia, Myeloid, Acute / metabolism*
-
Neoplastic Stem Cells / cytology*
-
Neoplastic Stem Cells / drug effects*
-
Protein Kinase Inhibitors / pharmacology*
-
Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
-
Proto-Oncogene Proteins c-bcl-2 / metabolism*
Substances
-
Protein Kinase Inhibitors
-
Proto-Oncogene Proteins c-bcl-2